Search Clinical Trials
Sponsor Condition of Interest |
---|
Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute1
BioPorto Diagnostics
Acute Kidney Injury
The purpose of this research is to collect blood and urine from adult patients admitted
to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL)
assay (lab test) as an aid to identify patients at risk for acute kidney injury. expand
The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury. Type: Observational Start Date: Oct 2024 |
Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction
Northwestern University
Heart Failure
Heart Failure With Preserved Ejection Fraction
The purpose of this study is to identify changes in heart tissue structure and biological
function in patients with heart failure by performing an endomyocardial biopsy (EMB or
heart biopsy) during a right heart catheterization (RHC). The ultimate goal is to use
this information to develop new trea1 expand
The purpose of this study is to identify changes in heart tissue structure and biological function in patients with heart failure by performing an endomyocardial biopsy (EMB or heart biopsy) during a right heart catheterization (RHC). The ultimate goal is to use this information to develop new treatments for heart failure. Type: Observational [Patient Registry] Start Date: Nov 2024 |
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Allogene Therapeutics
Large B-cell Lymphoma
This is a randomized, open-label study in adult patients who have completed standard
first line of therapy for large B-cell lymphoma (LBCL) and achieved a complete response
or partial response suitable for observation, but who have minimal residual disease (MRD)
as detected by the Foresight CLARITY1 expand
This is a randomized, open-label study in adult patients who have completed standard first line of therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. The study is conducted in 2 consecutive parts that will be enrolled continuously. In Part A of the study, participants with MRD are randomized to one of two treatment arms or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide administered with or without the anti-CD52 monoclonal antibody, ALLO-647. Part A will culminate with the selection of the lymphodepletion regimen to advance to Part B. Part B will evaluate the selected lymphodepletion regimen followed by cema-cel as compared with observation. Type: Interventional Start Date: Jun 2024 |
Comparative-effectiveness of a Healthy Lifestyle and Asthma Management Program, In-person Vs. ONline
Massachusetts General Hospital
Overweight, Childhood
Obesity, Childhood
Asthma in Children
The goal of this study is to evaluate the effectiveness of CHAMPION
("Comparative-effectiveness of a Healthy lifestyle and Asthma Management Program,
In-person vs ONline"), a primary care-based intervention to address childhood obesity and
asthma, and test the effectiveness of a telehealth-only ver1 expand
The goal of this study is to evaluate the effectiveness of CHAMPION ("Comparative-effectiveness of a Healthy lifestyle and Asthma Management Program, In-person vs ONline"), a primary care-based intervention to address childhood obesity and asthma, and test the effectiveness of a telehealth-only version of the program. Intensive Health Behavior and Lifestyle Treatment (IHBLT), when delivered via telehealth vs. in-person among children with overweight or obesity and persistent asthma. Type: Interventional Start Date: Jul 2024 |
Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer
Massachusetts General Hospital
Lung Cancer
Multi-site randomized trial of the THRIVE digital health application versus usual care to
evaluate the effect of THRIVE on quality of life (QOL), physical and psychological
symptoms, coping, and self-efficacy in 250 patients with newly diagnosed advanced lung
cancer. expand
Multi-site randomized trial of the THRIVE digital health application versus usual care to evaluate the effect of THRIVE on quality of life (QOL), physical and psychological symptoms, coping, and self-efficacy in 250 patients with newly diagnosed advanced lung cancer. Type: Interventional Start Date: Aug 2024 |
Study of REM-422 in Patients with AML or Higher Risk MDS
Remix Therapeutics
Myelodysplastic Syndromes
Higher Risk Myelodysplastic Syndromes
Acute Myeloid Leukemia
Acute Myeloid Leukemia Refractory
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB
mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML expand
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML Type: Interventional Start Date: Apr 2024 |
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Eli Lilly and Company
Metastatic Solid Tumor
Recurrent Solid Tumor
Advanced Solid Tumor
Urinary Bladder Neoplasm
Triple Negative Breast Cancer
The purpose of this study is to find out whether the study drug, LY4101174, is safe,
tolerable and effective in participants with advanced, or metastatic solid tumors. The
study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase
Ib (dose-expansion). The study will l1 expand
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years. Type: Interventional Start Date: Mar 2024 |
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
Seagen Inc.
Breast Neoplasms
Gastroesophageal Junction Adenocarcinoma
HER2 Low Breast Neoplasms
HER2 Positive Breast Neoplasms
Stomach Neoplasms
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in
part of your body like your lungs or liver instead of your blood. Once they've grown
bigger in one spot or spread to other parts of the body, they're harder to treat. This is
called advanced or metastatic cance1 expand
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV, with or without tucatinib, is for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease. Type: Interventional Start Date: May 2024 |
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyro1
Bristol-Myers Squibb
Carcinoma, Non-Small-Cell Lung
The purpose of this study is to evaluate the efficacy and safety of repotrectinib and
crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive
non-small cell lung cancer (NSCLC). expand
The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC). Type: Interventional Start Date: Dec 2023 |
Pulsed Field Ablation (PFA) Vs Anti-Arrhythmic Drug (AAD) Therapy As a First Line Treatment for Per1
Boston Scientific Corporation
Persistent Atrial Fibrillation
The purpose of this study is to establish the safety and effectiveness of pulsed field
ablation as a first-line ablation treatment for subjects with persistent atrial
fibrillation as compared to subjects who received an initial treatment with
anti-arrhythmic drugs. expand
The purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with persistent atrial fibrillation as compared to subjects who received an initial treatment with anti-arrhythmic drugs. Type: Interventional Start Date: Dec 2023 |
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Mela1
IDEAYA Biosciences
Metastatic Uveal Melanoma
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen
(HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be
randomized to receive either IDE196 + crizotinib or investigator's choice of treatment
(pembrolizumab, ipilimumab + nivolumab1 expand
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine). Type: Interventional Start Date: Oct 2023 |
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fib1
United Therapeutics
Progressive Pulmonary Fibrosis
Interstitial Lung Disease
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil
in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period. expand
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period. Type: Interventional Start Date: Oct 2023 |
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and A1
AbbVie
Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions
in the axilla (underarm), inguinal (groin) and anogenital (anal/genital) regions. This
study will assess how safe and effective upadacitinib is in treating adult and adolescent
participants with moderate to se1 expand
Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal/genital) regions. This study will assess how safe and effective upadacitinib is in treating adult and adolescent participants with moderate to severe HS who have failed to respond to or are intolerant of anti-tumor necrosis factor (TNF) therapy. Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for ulcerative colitis, atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of HS. This study is "double-blinded", meaning that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo. This study is comprised of 3 periods. In Period 1, participants are randomized into 2 groups called treatment arms where each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. In Period 2, participants are placed into 6 different groups depending on their placement and results in Period 1. Period 3 is the long-term extension period where participants will continue treatment from Period 2. Approximately 1328 adult and adolescent participants diagnosed with HS will be enrolled in approximately 275 sites worldwide. Participants will receive oral tablets of upadacitinib or placebo once daily for 36 weeks in Period 1 and Period 2. Eligible participants from Period 1 and Period 2 will enter Period 3 and receive oral tablets of upadacitinib or placebo once daily for 68 weeks. Participants will be followed up for approximately 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular outpatient visits during the study. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires. Type: Interventional Start Date: Jun 2023 |
Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years
Massachusetts General Hospital
Diabetes Mellitus
Type 1 Diabetes
Diabetes Type1
Autoimmune Diabetes
The purpose of this study is to investigate if repeat bacillus Calmette-Guérin (BCG)
vaccinations can confer a beneficial immune and metabolic effect in new onset pediatric
Type 1 diabetes. expand
The purpose of this study is to investigate if repeat bacillus Calmette-Guérin (BCG) vaccinations can confer a beneficial immune and metabolic effect in new onset pediatric Type 1 diabetes. Type: Interventional Start Date: May 2023 |
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modul1
University of Minnesota
COVID-19
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that
immune modulation can improve outcomes in hospitalized patients. This trial is designed
to determine whether intensification of immune modulation early in the course of the
disease (while patients are on low f1 expand
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be provided as part of SOC in case of signs of disease progression (patient requires high flow nasal oxygen (HFNO) or more support) and/or if the patient has rapidly increasing oxygen requirement. Type: Interventional Start Date: Jul 2023 |
Just-in-time Interventions for Reducing Short-term Suicide Risk
Massachusetts General Hospital
Suicide
The goal of this study is to test the effects of just-in-time intervention strategies
aimed to promote implementation of the safety plan and its components at different levels
of suicidal urges and intent. The main questions the investigators aim to answer are:
1. What is the acceptability and f1 expand
The goal of this study is to test the effects of just-in-time intervention strategies aimed to promote implementation of the safety plan and its components at different levels of suicidal urges and intent. The main questions the investigators aim to answer are: 1. What is the acceptability and feasibility of the just-in-time intervention strategies? 2. What are the proximal effects of just-in-time intervention strategies aimed to promote use of the safety plan and its components? 3. What internal and external contextual factors moderate the just-in-time intervention effects? Participants (adults hospitalized for suicidal thoughts or behaviors) will: - Answer questions about current suicidal thoughts on their smartphone up to 4 times each day during both hospitalization and the 4 weeks after they leave the hospital - Each time they submit a survey, be immediately randomized to receive (or not receive) a just-in-time intervention tailored to their level of current suicidal thoughts - Answer brief follow-up questions on their smartphone within a couple hours of each randomization - Provide feedback on their experience with the just-in-time interventions Type: Interventional Start Date: Nov 2024 |
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated1
Ionis Pharmaceuticals, Inc.
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
The purpose of this study is to evaluate the safety and tolerability of extended dosing
with eplontersen in participants with ATTR-CM. expand
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM. Type: Interventional Start Date: Nov 2022 |
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo1
Pfizer
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental
Vitiligo (Active and Stable) Tranquillo expand
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo Type: Interventional Start Date: Dec 2022 |
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
Bristol-Myers Squibb
Carcinoma, Hepatocellular
The purpose of this study is to evaluate the safety and effectiveness of triplet therapy
of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants
with untreated advanced/metastatic hepatocellular carcinoma (HCC). expand
The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC). Type: Interventional Start Date: May 2022 |
Abatacept in Immune Checkpoint Inhibitor Myocarditis
Massachusetts General Hospital
Myocarditis Acute
Cancer
The primary aim is to test whether abatacept, as compared to placebo, is associated with
a reduction in major adverse cardiac events (MACE) among participants hospitalized with
myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE,
is a composite of first occurren1 expand
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure. Type: Interventional Start Date: Jun 2022 |
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metas1
Regor Pharmaceuticals Inc.
Breast Cancer
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety,
tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B
administered orally as monotherapy OR in combination with Hormonal Therapy in subjects
with HR+, HER2- locally advanced and unresectable1 expand
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable (Stage III) or metastatic (Stage IV) breast cancer whose disease has progressed during prior therapy with an approved CDK4/6i plus hormonal therapy. Type: Interventional Start Date: Mar 2022 |
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in1
Hoffmann-La Roche
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
The main objective of the study is to evaluate the efficacy of satralizumab compared with
placebo based on time from randomization to the first occurrence of an adjudicated MOGAD
relapse in the double-blind (DB) treatment period expand
The main objective of the study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period Type: Interventional Start Date: Aug 2022 |
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclero1
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Diffuse Cutaneous Systemic Sclerosis
Interstitial Lung Disease
The purpose of this study is to assess the safety and efficacy of tulisokibart in
participants with SSc-ILD. expand
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD. Type: Interventional Start Date: Jul 2022 |
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HE1
Greenwich LifeSciences, Inc.
Breast Cancer
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center,
Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive
subjects who are at high risk for disease recurrence and have completed both neoadjuvant
and postoperative adjuvant standard of car1 expand
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of care therapy. Treatment consists of 6 intradermal injections, Primary Immunization Series (PIS), over the first 6 months of treatment and 5 booster intradermal injections spaced 6 months apart. A third open-label arm will explore GLSI-100 immunotherapy in non-HLA-A*02 positive and HER2/neu positive subjects. Type: Interventional Start Date: Aug 2022 |
Pressure-enabled Delivery in Radioembolization (TriNav Study)
Massachusetts General Hospital
Liver Cancer
Hepatocellular Carcinoma
Metastatic Colorectal Cancer
The purpose of the study is to determine if the type of catheter used in the mapping
procedure prior to radioembolization improves the delivery of radioactivity to tumor(s)
in participants with liver cancer.
The name of the devices involved in this study are:
- Pressure Enabled Drug Delivery (1 expand
The purpose of the study is to determine if the type of catheter used in the mapping procedure prior to radioembolization improves the delivery of radioactivity to tumor(s) in participants with liver cancer. The name of the devices involved in this study are: - Pressure Enabled Drug Delivery (PEDD)/TriNav Infusion System - Standard 2.4F microcatheter, not otherwise specified Type: Interventional Start Date: Mar 2022 |
- Previous
- Next